Xiamen Amoytop Biotech Co Ltd
SSE:688278
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
42.3
83.41
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Xiamen Amoytop Biotech Co Ltd
Cash & Cash Equivalents
Xiamen Amoytop Biotech Co Ltd
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
X
|
Xiamen Amoytop Biotech Co Ltd
SSE:688278
|
Cash & Cash Equivalents
¥413m
|
CAGR 3-Years
28%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Cash & Cash Equivalents
¥15B
|
CAGR 3-Years
33%
|
CAGR 5-Years
32%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Cash & Cash Equivalents
¥3.8B
|
CAGR 3-Years
75%
|
CAGR 5-Years
55%
|
CAGR 10-Years
N/A
|
|
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Cash & Cash Equivalents
¥1.9B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
13%
|
CAGR 10-Years
7%
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Cash & Cash Equivalents
¥5.6B
|
CAGR 3-Years
3%
|
CAGR 5-Years
82%
|
CAGR 10-Years
19%
|
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Cash & Cash Equivalents
¥2.4B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
56%
|
CAGR 10-Years
N/A
|
|
Xiamen Amoytop Biotech Co Ltd
Glance View
Xiamen Amoytop Biotech Co. Ltd. engages in the research and development of genetic engineering technology. The company is headquartered in Xiamen, Fujian and currently employs 1,261 full-time employees. The company went IPO on 2020-01-17. The firm's main research and development direction is immune-related cytokine drugs, focusing on systemic immune solutions based on cytokine drugs, and its products mainly include Peginterferon alfa-2b Injection, rhGM-CSF (Recombinant Human Granulocyte/Macrophage Colony-Stimulating Factor for Injection), rHuG-CSF (Recombinant Human Granulocyte-Colony Stimulating Factor for Injection) and Recombinant Human Interleukin-11 for Injection. The firm distributes its products within domestic market and to overseas markets.
See Also
What is Xiamen Amoytop Biotech Co Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
413m
CNY
Based on the financial report for Dec 31, 2023, Xiamen Amoytop Biotech Co Ltd's Cash & Cash Equivalents amounts to 413m CNY.
What is Xiamen Amoytop Biotech Co Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
23%
Over the last year, the Cash & Cash Equivalents growth was 37%. The average annual Cash & Cash Equivalents growth rates for Xiamen Amoytop Biotech Co Ltd have been 28% over the past three years , 23% over the past five years .
You don't have any saved screeners yet
